BeiGene, Ltd.
06160
2023 9 30
13.09
571 XIVA
2023 9 30
2023 9 30
2023
2023 11 9
1995 (Private Securities Litigation
Reform Act of 1995)
1
10-Q
2023 11 10
Margaret Han Dugan Donald W. Glazer
Michael Goller Anthony C. Hooper Ranjeev Krishana
Thomas Malley Alessandro Riva Corazon (Corsee) D. Sanders
2
2023
7.81 5.95
102% 70%
3.58
130%
(ESCC)
BGNE
06160 688235
2023
(John V. Oyler)
(CLL)
10
3.577 130% CLL
(CHMP)
(R/R) (FL)
R/R CLL
3
(EC)
ESCC
(FDA)
(BLA) ESCC
(PDUFA) FDA 2024 7
2023
2023 9 30 7.813 2022
3.876 101.6%
(1)
9 30 9 30
2023 2022 2023 2022
$ $ $ $
398,229 133,431 815,059 347,180
270,084 108,104 632,391 264,373
128,145 25,327 182,668 82,807
287,935 233,077 831,399 636,241
284,981 233,077 825,809 636,241
2,954 – 5,590 –
85,583 17,995 153,273 46,634
30,664 5,200 76,487 9,205
54,919 12,795 76,786 37,429
9,561 3,125 24,639 5,771
781,308 387,628 1,824,370 1,035,826
(1)
4
2023 9 30 5.953 2022
3.495 70.3%
2023 2.458
2023
2.701
149.8% (TN) R/R CLL
(SLL) FDA
4,740
20.8%
(BTK)
2023
1.444
12.6%
PD-1
2023 83.8%
78.1%
2023 9 30 8.190
2022 7.494 9.3%
2023 9 30 2.154
2022 5.576
(BMS) 3.629
3.044
5
2023 9 30 0.16 0.15
(ADS) 2.06 2.01
2022 9 30 0.41 ADS 5.39
2023 9 30 32
2022 12 31 45
2023 9 30 7,820
5.619
2023
2023 10-Q
3 ALPINE
R/R CLL
(PFS)
(EMA)
(CHMP)
R/R
(FL)
13 TN R/
R CLL
R/R CLL
6
R/R (WM)
FDA
EC
ESCC
(NMPA)
FDA
ESCC BLA
PDUFA FDA 2024
7
NMPA
(sBLA)
PD-(L)1
(ES-SCLC) sBLA
NMPA
3 RATIONALE-315
(EFS)
II IIIA
(NSCLC)
Sonrotoclax R/R WM
(BGB-11417)
(NME) 1
BCL2 CCR8 (mAb)
DGK HPK1
7
3 ALPINE
R/R CLL/SLL PFS
2023
FDA
(sNDA)
2024 3 FDA
R/R FL
2023 2024
FDA
ESCC
FDA
ESCC
(PDUFA)
2024 7
2024
EMA
NSCLC
NSCLC
2023 FDA
(sBLA)
2024
(PMDA)
ESCC
8
2024
NMPA
II IIIA
NSCLC sBLA
2024 EMA
ESCC
sBLA
2023 3
ALPINE
R/R CLL/SLL
Sonrotoclax 2023
CLL
BTK CDAC 2023 12
(BGB-16673) (ASH) B
1
2024
TIGIT NSCLC 3
AdvanTIG-302
9
12 2023 ASH 24 3 ALPINE
R/R CLL/SLL
sonrotoclax TN CLL 1/2
2023 (ESMO) 10 5
o
(GC/GEJC)
3 RATIONALE-305
o 3 RATIONALE-315
II-IIIA (NSCLC)
2023
ES-SCLC 3 RATIONALE-312
100 9.3
2024
64,000
(ADC)
55.9 5.2
6
5
Zymeworks
HER2 ZW49(zanidatamab
zovodotin)
10
2023 2022
9 30 12 31
$ 3,187,881 $ 4,540,288
309,079 173,168
316,929 282,346
1,178,038 845,946
5,524,879 6,379,290
341,857 294,781
505,824 467,352
300 255,887
255,391 293,960
531,051 538,117
1,761,645 1,995,935
$ 3,763,234 $ 4,383,355
11
ADS ADS
9 30 9 30
2023 2022 2023 2022
$ 595,290 $ 349,506 $ 1,559,326 $ 915,590
186,018 38,122 265,044 120,236
781,308 387,628 1,824,370 1,035,826
96,309 76,543 274,088 212,953
453,259 426,363 1,284,607 1,194,485
364,421 322,892 1,087,954 948,868
1,287 187 1,662 563
915,276 825,985 2,648,311 2,356,869
(133,968) (438,357) (823,941) (1,321,043)
26,649 12,759 57,735 34,261
336,657 (125,640) 291,142 (243,290)
229,338 (551,238) (475,064) (1,530,072)
13,925 6,318 39,091 28,408
215,413 (557,556) (514,155) (1,558,480)
$ 0.16 $ (0.41) $ (0.38) $ (1.16)
$ 0.15 $ (0.41) $ (0.38) $ (1.16)
1,360,716,279 1,345,303,747 1,358,392,470 1,337,976,853
1,390,331,833 1,345,303,747 1,358,392,470 1,337,976,853
ADS
$ 2.06 $ (5.39) $ (4.92) $ (15.14)
$ 2.01 $ (5.39) $ (4.92) $ (15.14)
ADS
104,670,483 103,484,904 104,491,728 102,921,296
106,948,603 103,484,904 104,491,728 102,921,296
12
10,000
www.beigene.com.cn
1995 (Private Securities Litigation
Reform Act of 1995)
10-Q
+86 10 5895 8058 +86 21 31591070
ir@beigene.com media@beigene.com
13